Further evidence that MRI based measurement of midbrain neuromelanin may serve as a proxy measure of brain dopamine activity in psychiatric disorders
- 1 February 2021
- journal article
- editorial
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 46 (7) , 1231-1232
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH122139)
This publication has 6 references indexed in Scilit:
- Structural Magnetic Resonance Imaging All Over AgainJAMA Psychiatry, 2021
- RETRACTED ARTICLE: Association between neuromelanin-sensitive MRI signal and psychomotor slowing in late-life depressionNeuropsychopharmacology, 2020
- Schizophrenia, Dopamine and the Striatum: From Biology to SymptomsTrends in Neurosciences, 2019
- Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brainProceedings of the National Academy of Sciences, 2019
- Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET studyMolecular Psychiatry, 2018
- Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's diseaseNeuroReport, 2006